42 results
424B5
CPRX
Catalyst Pharmaceuticals Inc
5 Jan 24
Prospectus supplement for primary offering
5:15pm
committee with Santhera that will oversee the development of AGAMREE® for additional indications beyond DMD. Under our License Agreement with Santhera, we
424B5
CPRX
Catalyst Pharmaceuticals Inc
4 Jan 24
Prospectus supplement for primary offering
6:24pm
to coordinating financial assistance programs for eligible patients.
We have established a joint steering committee with Santhera that will oversee
8-K
EX-99.1
iwznifl2
28 Jul 23
Patrick J. McEnany Announces Intention to Retire as CEO of Catalyst Pharmaceuticals by Year-End
4:30pm
8-K
mnsse6lb1qxrjpnd
23 Jun 23
Catalyst Pharmaceuticals to License North American Rights to Vamorolone for Duchenne Muscular Dystrophy from Santhera Pharmaceuticals
4:31pm
8-K
EX-99.1
fql7kbp5
23 Jun 23
Catalyst Pharmaceuticals to License North American Rights to Vamorolone for Duchenne Muscular Dystrophy from Santhera Pharmaceuticals
4:31pm
8-K
EX-99.1
yyen9iuh9x4oaj 0tb
11 May 21
Catalyst Pharmaceuticals Announces First Quarter 2021 Financial Results and Provides Business Update
12:00am